A Randomised, Double-blind, Placebo Controlled Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics Profile of SLx-4090 Over 14 Days Dosing in Subjects With High Triglyceride Values

Trial Profile

A Randomised, Double-blind, Placebo Controlled Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics Profile of SLx-4090 Over 14 Days Dosing in Subjects With High Triglyceride Values

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2015

At a glance

  • Drugs KD 026 (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Sponsors Surface Logix
  • Most Recent Events

    • 29 Jan 2008 Status changed to completed in accordance with media release 9084666.
    • 21 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top